BioSpace News Archive

SELLAS Life Sciences Group, Inc. today announced that the first patients have been enrolled in the 60 mg dose cohort in its ongoing Phase 2a clinical trial of its novel and highly selective CDK9 inhibitor, SLS009, in combination with venetoclax and azacitidine (aza/ven) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies.

Velia Therapeutics, a biotechnology company focused on the discovery and development of a new generation of protein-based therapeutics that address the underlying causes of difficult-to-treat diseases, today announced that Michael York has joined the organization as chief business officer.

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. (“Biolojic”) today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma.

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase 1 trial of MZE829 in healthy volunteers.

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today announced the publication of a peer-reviewed article describing brain target engagement by CNM-Au8®, the company’s lead drug candidate.

Neogen Corporation announced that it is collaborating with the Cat Fanciers’ Association, a leading authority in feline advocacy.

Ambrx Biopharma, Inc., or Ambrx, announced that the Company will be added to the NASDAQ Biotechnology Index, effective prior to the market open on Monday, December 18, 2023.

Haystack Oncology, a Quest Diagnostics company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology’s industry-leading personalized MRD technology to help evaluate therapeutic response and provide molecular insights for a Rutgers Cancer Institute clinical trial examining early-stage triple-negative breast cancer patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.

PurMinds NeuroPharma (“PurMinds™" or the “Company”), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules,

The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced its pivotal STRIDE study ( NCT04535609 ) of mavodelpar in adult patients with primary